Loading
Cancer Cells and Metastasis / Breast Cancer Treatment Studies · Journal article
Jci Insight · September 7, 2026
Raises a question worth testing. It does not answer one.
This is a mechanistic study demonstrating that estrogen promotes tumor phenotypes in both ER+ and ER– breast cancer cell models and xenografts via a noncanonical UGDH/GPR30 pathway, with supporting single-cell sequencing of patient tumors. The work is exploratory and does not provide clinical efficacy data, hard outcomes, or therapeutic intervention results in humans.
In vitro cell-line study, in vivo xenograft study, and single-cell RNA sequencing of patient tumor specimens. ER+ and ER– breast cancer cell lines; immunocompromised mice (xenograft hosts implied); patient tumor specimens from metastatic breast cancer cases. Intervention: Estrogen stimulation; UGDH genetic knockdown. Compared with: Unstimulated controls or wild-type (non-knockdown) cell lines and xenografts.
Estrogen stimulation promoted migratory and proliferative phenotypes in both ER+ and ER– breast cancer cell lines in vitro UGDH knockdown blunted estrogen-stimulated tumor phenotypes in vitro, ex vivo, and in vivo across both ER+ and ER– models UGDH dysregulation was associated with metastatic breast cancer on single-cell sequencing of patient specimens
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This pathway mechanism may inform understanding of estrogen responsiveness in ER– breast cancer and potential resistance to aromatase inhibitors; however, no clinical trial data or therapeutic efficacy in patients is reported. Further translational and clinical investigation would be required before any practice application.
This is a mechanistic study using cell lines, animal models, and patient specimens to explore a signaling pathway; it raises questions about UGDH/GPR30 in estrogen-responsive breast cancer but does not report clinical outcomes or hard endpoints that would support practice change.
As stated by the source record.
This pathway mechanism may inform understanding of estrogen responsiveness in ER– breast cancer and potential resistance to aromatase inhibitors; however, no clinical trial data or therapeutic efficacy in patients is reported. Further translational and clinical investigation would be required before any practice application.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Estrogen can promote aggressive tumor phenotypes in estrogen receptor–positive (ER + ) breast cancer; however, ER – cell lines are not widely considered estrogen responsive. Noncanonical estrogen-stimulated pathways such as the membrane-bound G protein–coupled estrogen receptor ( GPR30 ) can mediate migratory and proliferative phenotypes in breast cancer and are postulated to promote resistance to aromatase therapies. Moreover, dysregulation of UDP-glucose 6-dehydrogenase ( UGDH ), a ubiquitously expressed enzyme critical to the metabolism of UDP-glucuronic acid into extracellular matrix precursors and hormone regulation, is associated with tumorigenesis. Here, we illustrated the impact of estrogen stimulation on tumor phenotypes in ER + and ER – cell models in vitro and in vivo. We then demonstrated UGDH ’s association with metastatic breast cancer via single-cell sequencing of patient specimens. Genetic knockdown of UGDH blunted estrogen-stimulated tumor phenotypes in vitro, ex vivo, and in vivo using both ER + and ER – breast cancer lines. Finally, we demonstrated that UGDH knockdown blunted noncanonical estrogen stimulation through GPR30. Ultimately, our study validated prior studies demonstrating estrogen-responsive malignant phenotypes in ER – breast cancer and demonstrated that estrogen-stimulated breast cancer progression can be mediated through noncanonical pathways (e.g., UGDH/GPR30 ), regardless of ER status.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.